Kaleido BioSciences Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 82
Employees
  • Stock Symbol
  • KLDO
Stock Symbol
  • Share Price
  • $2.21
  • (As of Friday Closing)

Kaleido BioSciences General Information

Description

Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.

Contact Information

Website
www.kaleido.com
Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
  • 18 Crosby Drive
  • Bedford, MA 01730
  • United States
+1 (617) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kaleido BioSciences Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.21 $2.14 $2.05 - $20.50 $94.1M 42.6M 144K -$2.24

Kaleido BioSciences Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 181,838 293,733 84,600
Revenue 855 975 0 0
EBITDA (84,941) (77,244) (85,729) (61,065)
Net Income (90,032) (81,620) (86,331) (61,744)
Total Assets 67,804 59,344 82,306 85,325
Total Debt 21,516 21,009 20,459 14,922
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kaleido BioSciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kaleido BioSciences‘s full profile, request access.

Request a free trial

Kaleido BioSciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Kaleido BioSciences‘s full profile, request access.

Request a free trial

Kaleido BioSciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbi
Biotechnology
Bedford, MA
82 As of 2020
00000
0000 0000-00-00
00000000 00000

0000000

aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Ex
0000000000000
Cambridge, MA
000 As of 0000
00000
000000000

00000 00

ipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim v
0000000000000
Lexington, MA
00.00
0000 0000-00-00
000000&0 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kaleido BioSciences Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Voyager Therapeutics Formerly PE-Backed Cambridge, MA 000 00000 000000000
00000 000000000000 Formerly VC-backed Lexington, MA 00.00 000000&0 00.00
0000000 Accelerator/Incubator Backed Labège, France 000.00 0000000000 000.00
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
0000 000000 Venture Capital-Backed Lyon, France 00 000.00 00000000 000.00
You’re viewing 5 of 42 competitors. Get the full list »

Kaleido BioSciences Patents

Kaleido BioSciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019377869-A1 Oligosaccharide compositions and methods of use thereof Pending 08-Nov-2018 0000000000
CA-3118909-A1 Oligosaccharide compositions and methods of use thereof Pending 08-Nov-2018 0000000000
US-20210164926-A1 Oligosaccharide compositions and methods of use thereof Pending 08-Nov-2018 0000000000
CA-3117061-A1 Methods of quantifying oligosaccharide preparations Pending 08-Nov-2018 00000000000
EP-3877423-A1 Methods of quantifying oligosaccharide preparations Pending 08-Nov-2018 C08B37/0003
To view Kaleido BioSciences’s complete patent history, request access »

Kaleido BioSciences Executive Team (19)

Name Title Board Seat Contact Info
Daniel Menichella Chief Executive Officer & Board Member
Rob Miller Ph.D President of Nutrition
William Duke Jr. Chief Financial Officer
Johan van Hylckama Vlieg Ph.D Chief Scientific Officer
Alison Long Chief Medical Officer
You’re viewing 5 of 19 executive team members. Get the full list »

Kaleido BioSciences Board Members (17)

Name Representing Role Since
Anne Prener MD Kaleido BioSciences Board Member 000 0000
Anthony Quinn Ph.D Self Board Member 000 0000
Daniel Menichella Kaleido BioSciences Chief Executive Officer & Board Member 000 0000
Geoffrey von Maltzahn Ph.D Self Board Member 000 0000
Grady Burnett Self Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Kaleido BioSciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kaleido BioSciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kaleido BioSciences‘s full profile, request access.

Request a free trial